Though much of Freenome’s focus has been on its blood test for the early detection of colorectal cancer, the company is also in the process of building out its multiomics platform to be able to test for other types of cancer, too.
A new acquisition aims to accelerate the latter goal. Freenome put down 13 million British pounds—or about $16.1 million—to absorb Oncimmune Limited and Oncimmune Europe GmbH, two subsidiaries of U.K.-based Oncimmune, another maker of early cancer diagnostics.